INNATE PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.245 EUR | +2.98% |
|
+6.40% | -14.31% |
| Apr. 15 | Sanofi: progress in hematology trial | CF |
| Apr. 15 | Innate Pharma: progress in hematology trial | CF |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 468.1 | 273.4 | 351.7 | 263.8 | 211.2 | 181.5 | - | - |
| Enterprise Value (EV) 1 | 268 | 101.9 | 276.1 | 204.6 | 158.7 | 115.8 | 59.88 | -52.44 |
| P/E ratio | -19.2 x | -4.27 x | -6.74 x | -4.51 x | -29.1 x | -15.5 x | 3.71 x | 2.92 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.45 x | 3.88 x | 14.2 x | 4.57 x | 3.43 x | 3.88 x | 2.44 x | 1.47 x |
| EV / Revenue | 3.12 x | 1.45 x | 11.2 x | 3.55 x | 2.57 x | 2.48 x | 0.8 x | -0.42 x |
| EV / EBITDA | -25.5 x | 2.66 x | -6.39 x | 7.06 x | -20.9 x | -6.4 x | 0.95 x | -0.68 x |
| EV / FCF | 7.96 x | -1.93 x | -4.62 x | -10.4 x | -4.82 x | 49.5 x | 1.4 x | -0.72 x |
| FCF Yield | 12.6% | -51.7% | -21.7% | -9.62% | -20.7% | 2.02% | 71.3% | -139% |
| Price to Book | 1.83 x | 1.75 x | 3.29 x | - | 4.08 x | 112 x | 1.64 x | 0.71 x |
| Nbr of stocks (in thousands) | 78,542 | 78,963 | 79,062 | 80,193 | 80,627 | 80,842 | - | - |
| Reference price 2 | 5.960 | 3.462 | 4.448 | 3.290 | 2.620 | 2.245 | 2.245 | 2.245 |
| Announcement Date | 3/10/20 | 3/18/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 85.81 | 70.45 | 24.7 | 57.67 | 61.64 | 46.78 | 74.41 | 123.6 |
| EBITDA 1 | -10.52 | 38.25 | -43.23 | 28.98 | -7.578 | -18.1 | 62.96 | 76.88 |
| EBIT 1 | -27.05 | -18.55 | -47.82 | -16.42 | -12.67 | -28.1 | 21.45 | 24.05 |
| Operating Margin | -31.52% | -26.33% | -193.6% | -28.48% | -20.55% | -60.06% | 28.83% | 19.45% |
| Earnings before Tax (EBT) 1 | -20.76 | -63.98 | -52.81 | -57.97 | -7.57 | -47.12 | -33.86 | -50.98 |
| Net income 1 | -20.76 | -63.98 | -52.81 | -58.1 | -7.57 | -25.71 | -21.37 | 1.584 |
| Net margin | -24.19% | -90.82% | -213.78% | -100.74% | -12.28% | -54.96% | -28.71% | 1.28% |
| EPS 2 | -0.3100 | -0.8100 | -0.6600 | -0.7300 | -0.0900 | -0.1450 | 0.6050 | 0.7700 |
| Free Cash Flow 1 | 33.65 | -52.71 | -59.79 | -19.69 | -32.91 | 2.341 | 42.71 | 72.69 |
| FCF margin | 39.22% | -74.82% | -242.02% | -34.14% | -53.39% | 5% | 57.4% | 58.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 67.84% | 94.55% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 4,589.93% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 3/18/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 26.66 | 36.74 | 33.71 | 15.69 | 9.017 | 45.59 | 12.08 | 40.2 | 21.44 | 5.494 | 28.27 | 10.3 | 15.3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -36.51 | -8.348 | -10.2 | -25.43 | -22.4 | 8.494 | -24.92 | -0.398 | -12.27 | -28.82 | -19.39 | - | - |
| Operating Margin | -136.94% | -22.72% | -30.26% | -162.11% | -248.39% | 18.63% | -206.2% | -0.99% | -57.23% | -524.45% | -68.6% | - | - |
| Earnings before Tax (EBT) 1 | -34 | -10.33 | -53.65 | -23.72 | -21.76 | 6.376 | -64.35 | 1.718 | -9.288 | -22.87 | -26.17 | - | - |
| Net income 1 | -34 | -10.33 | -53.65 | -23.72 | -29.09 | 6.303 | -64.41 | 1.718 | -9.288 | -22.87 | -26.17 | - | - |
| Net margin | -127.53% | -28.12% | -159.17% | -151.21% | -322.61% | 13.83% | -532.94% | 4.27% | -43.31% | -416.21% | -92.6% | - | - |
| EPS 2 | -0.5100 | - | - | -0.3000 | -0.3600 | 0.0800 | -0.8100 | 0.0200 | -0.1100 | -0.4300 | -0.0800 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 9/8/20 | 3/18/21 | 9/15/21 | 3/24/22 | 9/15/22 | 3/23/23 | 9/14/23 | 3/21/24 | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 200 | 171 | 75.6 | 59.2 | 52.6 | 65.7 | 122 | 234 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 33.7 | -52.7 | -59.8 | -19.7 | -32.9 | 2.34 | 42.7 | 72.7 |
| ROE (net income / shareholders' equity) | -10.8% | -11% | -34.5% | -21% | -14.3% | - | - | 79.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 3.250 | 1.970 | 1.350 | - | 0.6400 | 0.0200 | 1.370 | 3.180 |
| Cash Flow per Share | -0.0800 | -0.6600 | -0.7300 | - | - | - | - | - |
| Capex 1 | 1.27 | 11.3 | 1.33 | 0.54 | 0.35 | 3.7 | 9.2 | 14.4 |
| Capex / Sales | 1.48% | 16.01% | 5.38% | 0.93% | 0.57% | 7.91% | 12.36% | 11.65% |
| Announcement Date | 3/10/20 | 3/18/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.245
EUR
Average target price
6.27
EUR
Spread / Average Target
+179.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.31% | 194M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- IPH Stock
- Financials Innate Pharma
